PHAXIAM Therapeutics Investor Relations Material
Latest events
Q2 2024
PHAXIAM Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PHAXIAM Therapeutics SA
Access all reports
PHAXIAM Therapeutics S.A. is a biopharmaceutical company focused on developing innovative treatments for drug-resistant bacterial infections. Leveraging phages, which are viruses that specifically target and kill bacteria, the company is developing a portfolio aimed at combating some of the most challenging and resistant bacterial strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. PHAXIAM is also involved in advancing clinical-stage therapies, including eryaspase, which is being tested in late-stage clinical trials for conditions such as pancreatic cancer and acute lymphoblastic leukemia. The company is headquartered in Lyon, France, and its shares are listed on the Euronext Paris.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PHXM
Country
🇫🇷 France